Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market tendencies in insulinoma treatment are substantially stimulated by the growing incidence of insulinoma cases worldwide. As more individuals are recognized with this uncommon pancreatic neuroendocrine tumor, there is a growing demand for powerful remedy options. The insulinoma treatment market is witnessing a shift due to advancements in diagnostic technologies. Improved imaging strategies, including advanced MRI and CT scans, are resources for correct and early diagnosis of insulinomas. This trend contributes to timely intervention and complements the general remedy outcomes. Surgeons and healthcare experts are increasingly adopting minimally invasive surgical approaches for insulinoma treatment. Laparoscopic strategies and robot-assisted surgical procedures are gaining popularity, presenting sufferers with shorter recuperation instances, decreased postoperative aches, and decreased hassle prices.
Pharmaceutical companies are investing in enormous studies and improvements to find novel cures for insulinoma. This consists of the exploration of targeted drug treatments and customized medicine techniques to deal with the precise traits of insulin-secreting tumors. There is a substantive shift towards an affected person-centric method in drug improvement for insulinoma treatment. This entails thinking about the affected person's options, improving remedy adherence, and improving universal first-rate lifestyles. Pharmaceutical corporations are increasingly incorporating patients into the layout and improvement of the latest therapies. The insulinoma treatment market is increasing into rising economies with enhancing healthcare infrastructures. As the focus on insulinoma grows and diagnostic competencies are enhanced in these areas, there may be an improved demand for advanced treatment options.
Changes in healthcare regulations and reimbursement landscapes are influencing the market dynamics. Access to insulinoma treatments is impacted via reimbursement rules, and shifts in these regulations can drastically affect market tendencies and the adoption of precise cures. Precision remedy is gaining traction in insulinoma treatment. Tailoring treatments based on the man or woman characteristics of each affected person's tumor, consisting of genetic and molecular profiles, is becoming extra commonplace. This technique aims to optimize treatment efficacy while minimizing negative results. Recognizing the significance of early detection and remedy, there may be an emphasis on patient education and focus initiatives. Healthcare organizations and advocacy organizations are running to educate both healthcare professionals and the general public about insulinoma and its symptoms and to provide remedy options.
Insulinoma Market Highlights:
Insulinoma Market Overview
The Insulinoma Market is expected to reach USD 5,632.6 Million by 2030 at 6.9% CAGR during the forecast period 2022-2030.Insulinoma is a rare form of tumour of the beta cells of pancreas resulting in an excessive secretion of insulin, leading to hypoglycaemia. Most insulinomas are benign, however a few metastasize. The symptoms of insulinoma are hypoglycaemia and associated symptoms such as blurred vision, lethargy, diplopia, light headedness, and convulsions, unconsciousness, which can also be life-threatening. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms such as palpitations, tachycardia, sweating, hunger, anxiety etc. are caused by catecholaminergic response to hypoglycaemia triggered by insulinomas.
Insulinomas occur in people between the ages of 40 and 60 and grow slowly. The exact causes of insulinoma are unknown, however, patients with multiple endocrine neplasia type 1 syndrome or von Hippel-Landau syndrome are more at risk. According to a cancer research, 10% of insulinomas are cancerous and approximately 10% of patients diagnosed with insulinoma have more than one tumour. Insulinomas affect between up to five people out of one million each year.
Surgery is the definitive treatment for insulinomas and 90% of patients are cured of the condition. However, surgery can cause diabetes if significant amount of the pancreas are removed. The development of minimal invasive surgery procedures such as laparoscopy has resulted in replacement of open pancreatomy which was once the gold standard of treatment. The market constraints are lack of awareness, misdiagnosis of the disease, risk of surgery, high cost of treatment etc.
March 2021: Zealand Pharma A/S, a biotechnology company that aims to bring innovation to the market through the development of innovative peptide therapeutics, announced today that the U.S. The Food and Drug Administration (FDA) has approved Zegalogue® (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older. This sanction will facilitate the ability of suitable children and adults with diabetes to manage sudden and severe hypoglycemia, which can rapidly escalate from a mild occurrence to an emergency. The clinical significance of the extent and consistency of the effect observed in the Phase 3 pivotal studies is underscored by the fact that minutes are crucial in severe hypoglycemia. Zegalogue resolved severe hypoglycemia after administration, with a median time to blood glucose recovery of 10 minutes in these clinical studies. A critical drop in blood glucose levels, which is predominantly associated with insulin therapy, is the cause of severe hypoglycemia, an acute, life-threatening condition that is one of the most feared complications of diabetes treatment. The prevalence of severe hypoglycemia among children under the age of 18 is particularly high, with 7 out of 100 children diagnosed with diabetes on insulin reporting such episodes within the past six months. Although patients have the capacity to monitor and adjust their blood glucose levels to maintain appropriate glycemic control, it is not always feasible to prevent a severe hypoglycemic event.
July 2021: Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company that utilizes its innovative formulation technology platforms to create and market injectable and infusible drug formulations that are ready to use, announced that Gvoke HypoPen™ (glucagon injection) is now available by prescription in the United States for the treatment of severe hypoglycemia in adults and children with diabetes aged 2 years and older. The Gvoke HypoPen is the first premixed autoinjector that is ready to use and does not have a visible needle. It contains glucagon. Xeris is dedicated to guaranteeing that patients have access to this significant new development. Using the Gvoke® copay savings card, eligible commercially insured patients may pay as little as $0 for a two-pack of Gvoke HypoPen for a limited time. Additionally, Xeris provides a Patient Assistance Program to assist individuals who meet the eligibility criteria for Gvoke.
Research Methodology 
Intended Audience
- Global insulinoma treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities
Figure 1 Global insulinoma market by types, 2016 (%)
Insulinoma Market Segmentation
The global insulinoma market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as benign, and metastasize.
Based on diagnosis, the market has been segmented as blood test, endoscopic ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and others.
Based on treatment, the market has been segmented as surgery, drugs, radiofrequency ablation, chemotherapy and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Insulinoma Market Regional Analysis
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drives the insulinoma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of insulinoma treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran.
The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However, Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market.
Key Players in the Global Insulinoma Market
Some of key players profiled in the report are
- Abcam plc,
- cironpharma,
- Pfizer Plc.,
- Entax Medical,
- Olympus,
- Boston Scientific Corporation,
- Medtronic,
- Cook Medical,
- Cook Medical, Inc., and
- others.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
